The current situation of cancer morbidity and mortality in the light of the National Cancer Registry, Hungary.
Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. Treatment strategies for advanced prostate cancer.
Actualities in the medical treatment of metastatic prostate cancer. Novelties in diagnostics and treatment of prostate cancer. Androgen-deprivation therapy alone prostate cancer treatment with injections with docetaxel in non-castrate metastatic prostate cancer GETUG-AFU 15 : a randomised, open-label, phase 3 trial.
Lancet Oncol. J Clin Oncol. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.
N Engl J Med. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer STAMPEDE : survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet ; — Eur Urol. Ann Oncol.
Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer. Abiraterone and increased survival in metastatic prostate cancer.
Abiraterone in metastatic prostate cancer without previous chemotherapy. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.
Slowing growth of bladder, breast cancer cells
Abiraterone for prostate cancer not previously treated with hormone therapy. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer Prostatic Dis.